takeda pharmaceutical co

Phase 1/2 Results For Takeda’s Norovirus Vaccine

Takeda has announced the results of a Phase 1/2 study of its norovirus vaccine candidate which was found to be well tolerated.

Takeda And New Institute In Early-Stage Drug Discovery Partnership

Takeda will partner the newly formed Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) in early-stage drug discovery.

Norgine, Takeda Receive NDA Approval For OBLEAN Tablets 120mg In Japan

The Japanese Ministry of Health, Labor and Welfare has approved an NDA for OBLEAN® Tablets 120mg for the treatment of obesity with complications.

Vedolizumab Shown To Be Effective For Treating Inflammatory Bowel Diseases

The results from two phase 3 studies evaluating vedolizumab for the treatment of ulcerative colitis and Crohn's disease have been published.

Takeda Receives Marketing Authorization For NESINA In China

The China Food and Drug Administration has issued an Import Drug License for Takeda's type 2 diabetes drug.

Oral Rheumatoid Arthritis Treatment XELJANZ® Launched In Japan

Pfizer and Takeda Pharmaceutical have launched their rheumatoid arthritis drug XELJANZ® (tofacitinib citrate) in Japan.

Japan Launches Public-Private Partnership To Fight Neglected Diseases

The Global Health Innovative Technology Fund, a new public-private partnership, is taking Japanese R&D to the global fight against infectious disease.

Takeda Submits NDA Application For Cell Culture-Based H5N1 Vaccines

Takeda Pharma has submitted New Drug Applications for cell culture-based H5N1 influenza vaccines to the Ministry of Health, Labor and Welfare in Japan.

Takeda And Resolve Therapeutics To Develop Lupus Treatments

Takeda Pharma and Resolve Therapeutics have entered into a partnership to develop compounds for the treatment of lupus and other autoimmune diseases.